Published: 2022-01-28

Epidemiological profile of Parkinson’s disease: a hospital based descriptive study

Maanasa R., R. Lakshmi Narasimhan, Kalpana S., Valarmathi S., Srinivas G.


Background: Parkinson’s disease (PD), in general, is categorized into five stages based on Hoehn and Yahr staging marking its clinical progression, and is associated with various comorbidities. The diagnosis of PD, however, is relied on clinical manifestations that occur after significant neurological damage in patients. Objective of current study was to study the epidemiological profile of PD patients to identify their stage at diagnosis, associated comorbidities and their treatment-seeking behaviour. 

Methods: A descriptive study was conducted at the Movement disorders outpatient department where a total of sixty patients with a clinical diagnosis of PD were enrolled. They were correlated with the Unified Parkinson Disease Rating Scale for staging assessment and questioned regarding other chronic illness they suffer, if any, using a standardized questionnaire for comorbidity assessment and treatment procedure they underwent.

Results: The patients reported for the study were mostly males (63%) with a mean age of 58 years. Among them, 90% of patients were at Stage I and II of illness and 63% had some comorbidity like Hypertension while 37% of patients had no comorbidity. Most of them (58%) were diagnosed and treated immediately on the appearance of the first clinical symptom at Government institutions. Also, we found that 70% of patients had no awareness of PD. 

Conclusions: Thus we conclude that the early stage of disease observed in most patients, despite longer duration may suggest that early diagnosis can help in alleviation of symptoms. However, this observation needs a larger study to provide better and conclusive evidence. 



Parkinson’s disease, Staging, Comorbidity, Treatment seeking behaviour, Awareness

Full Text:



Santiago JA, Bottero V, Potashkin JA. Biological and clinical implications of comorbidities in Parkinson’s disease. Front Aging Neurosci. 2017;9:394.

Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson’s disease. Neurology. 1993;43(9):1693-7.

Noyce AJ, Lees AJ, Schrag AE. The prediagnostic phase of Parkinson’s disease. J Neurol Neurosurg Psychiatr. 2016;87(8):871-8.

Stages of Parkinson’s, Parkinson’s Foundation. Available at: Understand-ing-Parkinsons/What-is-Parkinsons/Stages-of-Parkinsons. Accessed on 16 August 2020.

Wang X, Zeng F, Jin W-S. Comorbidity burden of patients with Parkinson’s disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China. Sci Rep. 2017;7:795-9.

Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612-7.

Krüger R, Klucken J, Weiss D. Classification of advanced stages of Parkinson’s disease: translation into stratified treatments. J Neural Transm. 2017; 124(8):1015-27.

Breen DP, Evans JR, Farrell K, Brayne C, Barker RA. Determinants of delayed diagnosis in Parkinson’s disease. J Neurol. 2013;260(8):1978-81.